Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02659293 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Nov 2025 to Nov 2027
    • Study completion date: Nov 2026 to Nov 2027
    v13
  2. Primary completion date: Nov 2024 to Nov 2025v12
  3. 2 versions Re-verified since Apr 26, 2023, no change to tracked fieldsv10-v11
  4. Primary completion date: Mar 2021 to Nov 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: May 2022 to Nov 2026
    • Site details revised at 3 of 3 sites
    v9
  5. Primary completion date: Mar 2020 to Mar 2021v8
Show 6 earlier versionsHide 6 earlier versions
  1. Primary completion date: Mar 2019 to Mar 2020
    • Study completion date: May 2020 to May 2022
    v7
  2. Primary endpoint revisedv6 Show 4 more changesShow less
    • Primary completion date: Jan 2020 to Mar 2019
    • Interventions: Carfilzomib (Drug), Dexamethasone (Drug), Lenalidomide (Drug) to Carfilzomib (Drug), Dexamethasone (Drug), Lenalidomide (Control) (Drug), Lenalidomide (Drug)
    • Secondary endpoints: 2 to 3
    • Eligibility criteria expanded, about 5 words
  3. Primary completion date: Jan 2018 to Jan 2020
    • Study sites: 2 to 3
    • Study completion date: May 2018 to May 2020
    v5
  4. Study sites: 1 to 2
    • Study completion date: May 2018
    • Start date: Apr 2016 to Apr 26, 2016
    v4
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Mar 2016 to Apr 2016
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 3 randomized trial of carfilzomib, lenalidomide, dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma, eligible to subjects who completed autologous stem cell transplant for symptomatic myeloma who are considered for lenalidomide maintenance.
Trial Details
NCT Number NCT02659293
Lead Sponsor University of Chicago
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov